Novartis confirms plans for spin-off of Sandoz business

26 Sep 2023
·
Deals
www.pharmaceutical-technology.com
Acquisition
Novartis confirms plans for spin-off of Sandoz business
Preview
Source: Pharmaceutical Technology
The latest development comes after Novartis revealed its plans to separate the Sandoz business in August 2022. Credit: OleksSH/Shutterstock.com.
Novartis has confirmed plans for the complete spin-off of its generics and biosimilars business, SandozSandoz, following approval from shareholders.
New Sandoz Group shares and American depositary receipts (ADRs) will begin trading on 4 October 2023.
Recommended Reports
Novartis confirms plans for spin-off of Sandoz business
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Ramelteon in Delirium GlobalData
Novartis confirms plans for spin-off of Sandoz business
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Midazolam Odt in Sedation GlobalData
View allCompanies IntelligenceNovartis AGSandoz IncAstellasView all
Sandoz will be included in the Swiss Performance Index, the Swiss Leader Index and other Swiss indices.
Novartis has also obtained approvals to list Sandoz shares from regulatory authorities including the SIX Exchange Regulation.
The latest development follows the company’s announcement in August 2022 of plans to separate the Sandoz business and establish an independent company.
Sandoz obtained $3.75bn (SFr3.42bn) in debt financing from a number of banks that will provide $1.25bn via a revolving credit facility, which will serve as an undrawn backstop provision.
The spin-off will conclude with the distribution of Sandoz shares and ADRs in a 1:5 ratio to Novartis shareholders and ADR holders, respectively.
In a press release, Novartis noted: “Completion of the proposed spin-off is subject to satisfaction of certain conditions, including no event outside of the control of Novartis preventing the spin-off and no material adverse change.
“There can be no assurance regarding the ultimate timing of the proposed transaction or that the transaction will be completed.”
In August 2023, Sandoz also acquired global brand rights for Astellas’ antifungal agent Mycamine (micafungin sodium).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.